Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 30507 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 49597 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 55796 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 56327 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 59767 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 62613 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 67702 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 68522 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 77028 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 79804 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 80886 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 86756 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 99165 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 99206 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 100705 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 112051 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 112880 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 134316 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 141160 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 149389 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 172503 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 210378 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 247461 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | 338769 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | Peak area normalized | male | Normoglycemic | no neuropathy | |
Reversed phase POSITIVE ION MODE | NICOTINAMIDE (M+H)+ | Peak area normalized | male | Pre-diabetic | Neuropathy |